Home Stock

Stock Research: GlaxoSmithKline Pharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

GlaxoSmithKline Pharmaceuticals

NSI:GLAXO INE159A01016
17
  • Value
    8
  • Growth
    61
  • Safety
    Safety
    75
  • Combined
    29
  • Sentiment
    21
  • 360° View
    360° View
    17
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company manufacturing, distributing, and trading in pharmaceuticals. The company operates in vaccines, specialty, and general medicine, with popular brands including Augmentin, Calpol, Shingrix, and Nucala. It operates primarily in India. In the last fiscal year, the company had 3113 employees, a market cap of $6242 millions, profits of $262 millions, and revenue of $439 millions.

more

ANALYSIS: With an Obermatt 360° View of 17 (better than 17% compared with alternatives), overall professional sentiment and financial characteristics for the stock GlaxoSmithKline Pharmaceuticals are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for GlaxoSmithKline Pharmaceuticals. The consolidated Growth Rank has a good rank of 61, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 61% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 75 which means that the company has a financing structure that is safer than 75% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 8 which means that the share price of GlaxoSmithKline Pharmaceuticals is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 92% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 21, which means that professional investors are more pessimistic about the stock than for 79% of alternative investment opportunities. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Liquidity
Country United Kingdom
Industry Pharmaceuticals
Size Medium
Website india-pharma.gsk.com
Index
GlaxoSmithKline Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 20-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
8 13 17 29
Growth
61 87 25 31
Safety
Safety
75 77 79 65
Sentiment
21 77 32 1
360° View
360° View
17 79 16 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
55 74 43 13
Opinions Change
50 94 50 50
Pro Holdings
n/a 54 77 49
Market Pulse
37 46 7 5
Sentiment
21 77 32 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
8 13 17 29
Growth
61 87 25 31
Safety Safety
75 77 79 65
Combined
29 77 19 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
20 1 12 16
Price vs. Earnings (P/E)
11 19 12 20
Price vs. Book (P/B)
5 5 10 7
Dividend Yield
49 56 74 76
Value
8 13 17 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
68 44 28 10
Profit Growth
44 92 45 88
Capital Growth
97 65 25 7
Stock Returns
24 77 71 53
Growth
61 87 25 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
89 92 90 82
Refinancing
14 18 26 22
Liquidity
98 92 92 80
Safety Safety
75 77 79 65

Similar Stocks

Discover high‑ranked alternatives to GlaxoSmithKline Pharmaceuticals and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Genus

LSE:GNS
Country: United Kingdom
Industry: Biotechnology
Size: Medium
Full Stock Analysis

ZIGUP

LSE:ZIG
Country: United Kingdom
Industry: Specialized Consumer Services
Size: Medium
Full Stock Analysis

Costain

LSE:COST
Country: United Kingdom
Industry: Construction & Engineering
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews